<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03578172</url>
  </required_header>
  <id_info>
    <org_study_id>KYXM-2018001</org_study_id>
    <nct_id>NCT03578172</nct_id>
  </id_info>
  <brief_title>HMG Stimulation Versus HRT for Endometrial Preparation Prior to Blastocyst Transfer in Moderate to Severe IUA Patients</brief_title>
  <official_title>Randomized, Controlled Trial to Assess the Efficacy of Human Menopausal Gonadotrophin Stimulation and Hormone Replacement Therapy for Endometrial Preparation Prior to Blastocyst Transfer in Moderate to Severe Intrauterine Adhesion Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of endometrial preparation using either human menopausal gonadotrophin (HMG)
      stimulation and hormone replacement therapy (HRT) prior to blastocyst transfer in patients
      with moderate to severe intrauterine adhesion (IUA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2018</start_date>
  <completion_date type="Actual">November 20, 2019</completion_date>
  <primary_completion_date type="Actual">October 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>10th week after embryo transfer</time_frame>
    <description>Ongoing pregnancy is defined as the presence of a gestational sac with foetal heartbeat by transvaginal ultrasound at 10th week after embryo transfer（ET）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cycle cancellation rate</measure>
    <time_frame>the day of embryo transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>4th weeks after embryo transfer</time_frame>
    <description>Sacs seen in early ultrasound divided by the number of embryos transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>4th weeks after embryo transfer</time_frame>
    <description>Number of patients with ultrasound evidence of pregnancy divided by the number of embryo transfers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early miscarriage rate</measure>
    <time_frame>12th weeks gestational age</time_frame>
    <description>Number of losses of clinical pregnancies divided by number of clinical pregnancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy rate</measure>
    <time_frame>4th weeks after embryo transfer</time_frame>
    <description>number of pregnancies with a transient elevation of serum human chorionic gonadotropin(β-hCG) level (&gt;10 mIU/ml) divided by number of embryo transfers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Infertility, Female</condition>
  <condition>Intrauterine Adhesion</condition>
  <arm_group>
    <arm_group_label>Experimental-HMG stimulation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women will be subjected to ovarian stimulation for endometrial preparation using human menopausal gonadotrophin before blastocyst transfer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control-HRT group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will be subjected to hormone replacement therapy for endometrial preparation before blastocyst transfer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human menopausal gonadotrophin</intervention_name>
    <description>experimental group:Women will be given HMG 37.5-150IU daily followed by monitoring of the follicular growth (folliculometry) when serum Estradiol (E2)＜100pg/ml，progesterone (P)＜1ng/ml. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle ≥20mm in diameter followed by luteal phase support (using progesterone supplements) after 24 hours.</description>
    <arm_group_label>Experimental-HMG stimulation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hormone replacement therapy</intervention_name>
    <description>Women will be given 17 β-estradiol hemihydrate 2 mg and estrogen gel 5 g daily from day 3 of the cycle then the endometrial thickness will be assessed on day 7 by transvaginal sonography (TVS). If the endometrium is ≥ 9 mm, luteal phase support (using progesterone supplements) will be started but if the endometrium is &lt; 9 mm, estradiol will be continued until reaching appropriate endometrial thickness and then the luteal phase support will be started. The cycle will be cancelled If the estradiol administration ＞60 days.</description>
    <arm_group_label>Control-HRT group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 18~23 kg/m2

          -  Women with moderate to severe IUA as defined by the American Fertility Society
             classification (1988)

          -  Presence of at least 3 cryopreserved cleavage-stage embryos (including 1 good quality)
             or blastocysts

        Exclusion Criteria:

          -  Using embryos from donor oocytes

          -  Preimplantation genetic diagnosis(PGD)/Preimplantation genetic screening(PGS) cycles

          -  Moderate or severe endometriosis

          -  Untreated unilateral or bilateral hydrosalpinx

          -  Uterine adenomyosis, uterine myoma (submucous,intramural myoma &gt;4 cm),＞1cm septate
             uterus, double uterus, bicornuate uterus, unicornuate uterus
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Reproductive &amp; Genetic Hospital of CITIC-XIANGYA</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2018</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menotropins</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

